CN100342858C - 薯蓣总皂甙在制备抗阿司匹林抵抗药物中的应用 - Google Patents
薯蓣总皂甙在制备抗阿司匹林抵抗药物中的应用 Download PDFInfo
- Publication number
- CN100342858C CN100342858C CNB2003101220405A CN200310122040A CN100342858C CN 100342858 C CN100342858 C CN 100342858C CN B2003101220405 A CNB2003101220405 A CN B2003101220405A CN 200310122040 A CN200310122040 A CN 200310122040A CN 100342858 C CN100342858 C CN 100342858C
- Authority
- CN
- China
- Prior art keywords
- aspirin
- total saponin
- rhizoma dioscoreae
- application
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 150000007949 saponins Chemical class 0.000 title claims abstract description 43
- 229930182490 saponin Natural products 0.000 title claims abstract description 42
- 239000001397 quillaja saponaria molina bark Substances 0.000 title claims abstract description 41
- 239000003814 drug Substances 0.000 title claims abstract description 30
- 229960001138 acetylsalicylic acid Drugs 0.000 title claims description 60
- 238000004519 manufacturing process Methods 0.000 title description 2
- 238000000034 method Methods 0.000 claims abstract description 17
- 238000000194 supercritical-fluid extraction Methods 0.000 claims abstract description 3
- 238000003809 water extraction Methods 0.000 claims abstract description 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 63
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 15
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 13
- 238000002360 preparation method Methods 0.000 claims description 13
- 238000011282 treatment Methods 0.000 claims description 13
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 12
- 229940079593 drug Drugs 0.000 claims description 9
- 230000003637 steroidlike Effects 0.000 claims description 9
- 206010002383 Angina Pectoris Diseases 0.000 claims description 7
- 208000029078 coronary artery disease Diseases 0.000 claims description 7
- 150000002338 glycosides Chemical group 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 230000002255 enzymatic effect Effects 0.000 claims description 2
- 238000002955 isolation Methods 0.000 claims description 2
- 208000025870 aspirin resistance Diseases 0.000 abstract description 26
- 235000002722 Dioscorea batatas Nutrition 0.000 abstract 2
- 235000006536 Dioscorea esculenta Nutrition 0.000 abstract 2
- 240000001811 Dioscorea oppositifolia Species 0.000 abstract 2
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 abstract 2
- 150000003431 steroids Chemical class 0.000 abstract 2
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 abstract 1
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 abstract 1
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 abstract 1
- 235000017709 saponins Nutrition 0.000 description 31
- 230000000694 effects Effects 0.000 description 21
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 238000006356 dehydrogenation reaction Methods 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 210000002700 urine Anatomy 0.000 description 13
- 239000000047 product Substances 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 239000003146 anticoagulant agent Substances 0.000 description 7
- HDXIQHTUNGFJIC-UHFFFAOYSA-N (25R)-spirost-5-en-3beta-ol 3-O-<O-alpha-L-rhamnopyranosyl-(1-->2)-beta-D-glucopyranoside> Natural products O1C2(OCC(C)CC2)C(C)C(C2(CCC3C4(C)CC5)C)C1CC2C3CC=C4CC5OC1OC(CO)C(O)C(O)C1OC1OC(C)C(O)C(O)C1O HDXIQHTUNGFJIC-UHFFFAOYSA-N 0.000 description 6
- VNONINPVFQTJOC-RXEYMUOJSA-N Collettiside III Natural products O([C@@H]1[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@H](CO)O[C@@H]1O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]5[C@H](C)[C@@]6(O[C@H]5C4)OC[C@H](C)CC6)CC3)CC=2)CC1)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1 VNONINPVFQTJOC-RXEYMUOJSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 239000012141 concentrate Substances 0.000 description 6
- VNONINPVFQTJOC-ZGXDEBHDSA-N dioscin Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O[C@H]1[C@@H]([C@H](O)[C@@H](O)[C@H](C)O1)O)O[C@@H]1CC2=CC[C@H]3[C@@H]4C[C@H]5[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@@H]([C@]1(OC[C@H](C)CC1)O5)C)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O VNONINPVFQTJOC-ZGXDEBHDSA-N 0.000 description 6
- CJNUQCDDINHHHD-APRUHSSNSA-N dioscin Natural products C[C@@H]1CC[C@@]2(OC1)O[C@H]3C[C@H]4[C@@H]5CC=C6C[C@H](CC[C@@H]6[C@H]5CC[C@]4(C)[C@H]3[C@@H]2C)O[C@@H]7O[C@H](CO)[C@@H](O[C@@H]8O[C@@H](C)[C@H](O)[C@@H](O)[C@H]8O)[C@H](O)[C@H]7O[C@@H]9O[C@@H](C)[C@H](O)[C@@H](O)[C@H]9O CJNUQCDDINHHHD-APRUHSSNSA-N 0.000 description 6
- 210000003743 erythrocyte Anatomy 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 208000010125 myocardial infarction Diseases 0.000 description 6
- VNONINPVFQTJOC-UHFFFAOYSA-N polyphyllin III Natural products O1C2(OCC(C)CC2)C(C)C(C2(CCC3C4(C)CC5)C)C1CC2C3CC=C4CC5OC(C(C1O)OC2C(C(O)C(O)C(C)O2)O)OC(CO)C1OC1OC(C)C(O)C(O)C1O VNONINPVFQTJOC-UHFFFAOYSA-N 0.000 description 6
- 230000000391 smoking effect Effects 0.000 description 6
- 102000008186 Collagen Human genes 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 5
- 241000374766 Dioscorea panthaica Species 0.000 description 5
- 235000009926 Dioscorea panthaica Nutrition 0.000 description 5
- 229920001436 collagen Polymers 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 230000029142 excretion Effects 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 208000006011 Stroke Diseases 0.000 description 4
- 230000000202 analgesic effect Effects 0.000 description 4
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 230000000747 cardiac effect Effects 0.000 description 4
- 210000004351 coronary vessel Anatomy 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 230000004089 microcirculation Effects 0.000 description 4
- 230000010118 platelet activation Effects 0.000 description 4
- 230000003405 preventing effect Effects 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 4
- XNRNNGPBEPRNAR-JQBLCGNGSA-N thromboxane B2 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1OC(O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O XNRNNGPBEPRNAR-JQBLCGNGSA-N 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 206010002388 Angina unstable Diseases 0.000 description 3
- 241000908494 Dioscorea nipponica Species 0.000 description 3
- 235000017008 Dioscorea nipponica Nutrition 0.000 description 3
- 208000031226 Hyperlipidaemia Diseases 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 208000007814 Unstable Angina Diseases 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 230000000702 anti-platelet effect Effects 0.000 description 3
- 229940127219 anticoagulant drug Drugs 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 3
- 208000028867 ischemia Diseases 0.000 description 3
- 229960002748 norepinephrine Drugs 0.000 description 3
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000001117 sulphuric acid Substances 0.000 description 3
- 235000011149 sulphuric acid Nutrition 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 2
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 2
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 101150071146 COX2 gene Proteins 0.000 description 2
- 101100496968 Caenorhabditis elegans ctc-1 gene Proteins 0.000 description 2
- 101100114534 Caenorhabditis elegans ctc-2 gene Proteins 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 244000281702 Dioscorea villosa Species 0.000 description 2
- 208000005189 Embolism Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010021703 Indifference Diseases 0.000 description 2
- 101100221647 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cox-1 gene Proteins 0.000 description 2
- 101150062589 PTGS1 gene Proteins 0.000 description 2
- 101150000187 PTGS2 gene Proteins 0.000 description 2
- 208000001435 Thromboembolism Diseases 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 206010000891 acute myocardial infarction Diseases 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 102000004139 alpha-Amylases Human genes 0.000 description 2
- 108090000637 alpha-Amylases Proteins 0.000 description 2
- 229940024171 alpha-amylase Drugs 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 229940114079 arachidonic acid Drugs 0.000 description 2
- 235000021342 arachidonic acid Nutrition 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 238000013172 carotid endarterectomy Methods 0.000 description 2
- 150000003943 catecholamines Chemical class 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000000916 dilatatory effect Effects 0.000 description 2
- 235000004879 dioscorea Nutrition 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000003859 lipid peroxidation Effects 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 230000036284 oxygen consumption Effects 0.000 description 2
- 238000013146 percutaneous coronary intervention Methods 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000011287 therapeutic dose Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical group OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 2
- 229960005080 warfarin Drugs 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- FZRCKLPSHGTOAU-UHFFFAOYSA-N 6-amino-1,4-dimethylcyclohexa-2,4-diene-1-carbaldehyde Chemical compound CC1=CC(N)C(C)(C=O)C=C1 FZRCKLPSHGTOAU-UHFFFAOYSA-N 0.000 description 1
- 244000152526 Agathosma crenulata Species 0.000 description 1
- 235000013388 Agathosma crenulata Nutrition 0.000 description 1
- 240000001592 Amaranthus caudatus Species 0.000 description 1
- 235000009328 Amaranthus caudatus Nutrition 0.000 description 1
- 206010059245 Angiopathy Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 235000009269 Barosma crenulata Nutrition 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 102000010907 Cyclooxygenase 2 Human genes 0.000 description 1
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 241000234272 Dioscoreaceae Species 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 241000237903 Hirudo Species 0.000 description 1
- 101000947178 Homo sapiens Platelet basic protein Proteins 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 102100036154 Platelet basic protein Human genes 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000007718 Stable Angina Diseases 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 235000012735 amaranth Nutrition 0.000 description 1
- 239000004178 amaranth Substances 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 229940067131 aspirin 100 mg Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 229940062650 buchu Drugs 0.000 description 1
- 230000008061 calcium-channel-blocking effect Effects 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000007211 cardiovascular event Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 150000002066 eicosanoids Chemical class 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 150000002505 iron Chemical class 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 210000000088 lip Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000012153 long-term therapy Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000036513 peripheral conductance Effects 0.000 description 1
- 230000036581 peripheral resistance Effects 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000009862 primary prevention Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000003331 prothrombotic effect Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000009863 secondary prevention Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 150000005856 steroid saponins Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 201000005665 thrombophilia Diseases 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 230000006441 vascular event Effects 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
阿司匹林(n=50例) | 薯蓣总皂甙(n=50例) | 阿司匹林与薯蓣总皂甙合用(n=50例) |
尿值11-脱氢TXB2(ng/mmol) | 尿值11-脱氢TXB2(ng/mmol) | 尿值11-脱氢TXB2(ng/mmol) |
30.24 | 30.94 | 19 |
1918.7830.4615.2637.24113611.633834.6413.4116.6827.630.1214.7415.5438.2527.6828.9436.5117.4515.3239.3537.659.2514.844728.4327.3227.0039.518.2537.4226.2630.4416.829.969.242524.2230.2434.4530.229.7827.63 | 1319.3612.2312.6331.8613.0835.6423.3210.389.5228.628.0121.9427.3215.2134.4210.6718.824.2528.6714.2531.5810.2522.4920.5211.2831.2810.5335.6616.3523.1110.9913.4819.532.728.5623.521530.2428.6215.4325.3613.9935.8910.02 | 8.3529.3617.6624.0217.6521.2332.779.2511.441125.6225.3212.7728.9211.0128.129.7430.2520.1115.2613.33258.59312529.7331.2510.2722.3511.29.0430.2512.814.7297268.7414.729.992518.4319.722.0537.05 |
10.13845.2715.2425.16±11.21 | 14.2321.3321.9621.4521.33579±7.563 | 7.910.8226.2519.0719.39421±8.919 |
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2003101220405A CN100342858C (zh) | 2003-12-31 | 2003-12-31 | 薯蓣总皂甙在制备抗阿司匹林抵抗药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2003101220405A CN100342858C (zh) | 2003-12-31 | 2003-12-31 | 薯蓣总皂甙在制备抗阿司匹林抵抗药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1634100A CN1634100A (zh) | 2005-07-06 |
CN100342858C true CN100342858C (zh) | 2007-10-17 |
Family
ID=34844347
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2003101220405A Expired - Lifetime CN100342858C (zh) | 2003-12-31 | 2003-12-31 | 薯蓣总皂甙在制备抗阿司匹林抵抗药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100342858C (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1111250A (zh) * | 1994-05-03 | 1995-11-08 | 厦门同安皂素厂 | 从薯蓣属植物中提取薯蓣皂素的方法 |
CN1240791A (zh) * | 1998-06-29 | 2000-01-12 | 广州市医药工业研究所 | 超临界流体萃取法从薯蓣属植物中提取薯蓣皂素 |
CN1415625A (zh) * | 2002-10-21 | 2003-05-07 | 吉林天药科技股份有限公司 | 薯蓣皂苷的制备方法、药物制剂及其医药新用途 |
CN1441059A (zh) * | 2003-02-24 | 2003-09-10 | 天津大学 | 生物酶催化协同浸取提取薯蓣皂素的方法 |
-
2003
- 2003-12-31 CN CNB2003101220405A patent/CN100342858C/zh not_active Expired - Lifetime
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1111250A (zh) * | 1994-05-03 | 1995-11-08 | 厦门同安皂素厂 | 从薯蓣属植物中提取薯蓣皂素的方法 |
CN1240791A (zh) * | 1998-06-29 | 2000-01-12 | 广州市医药工业研究所 | 超临界流体萃取法从薯蓣属植物中提取薯蓣皂素 |
CN1415625A (zh) * | 2002-10-21 | 2003-05-07 | 吉林天药科技股份有限公司 | 薯蓣皂苷的制备方法、药物制剂及其医药新用途 |
CN1441059A (zh) * | 2003-02-24 | 2003-09-10 | 天津大学 | 生物酶催化协同浸取提取薯蓣皂素的方法 |
Non-Patent Citations (1)
Title |
---|
黄山药总皂苷和薯蓣皂苷元抗高脂血症及体外抗血小板聚集的比较 马海英等,中国医院药学杂志,第22卷第6期 2002 * |
Also Published As
Publication number | Publication date |
---|---|
CN1634100A (zh) | 2005-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Amresh et al. | Toxicological screening of traditional medicine Laghupatha (Cissampelos pareira) in experimental animals | |
Ma et al. | Qi-dan-di-huang decoction alleviates diabetic nephropathy by inhibiting the NF-kappaB pathway | |
CN1569884B (zh) | 黄芪甲苷的制法及在制备防治糖尿病肾病药物中的应用 | |
CN100342858C (zh) | 薯蓣总皂甙在制备抗阿司匹林抵抗药物中的应用 | |
IBRAHIM et al. | Glucose and Lipid Lowering Potentials of Heliotropium indicum L. Leaves in Alloxan-Induced Hyperglycaemic Rats | |
CN102349898B (zh) | 槐果碱在制备治疗柯萨奇b病毒引发的病毒性扩张型心肌病的药物中的应用 | |
CN110227080A (zh) | 甘露葡萄糖醛酸多(寡)糖及其衍生物在制备治疗和/或预防2型糖尿病药物中的应用 | |
CN100553650C (zh) | 一种药物组合物在制备抗阿司匹林抵抗药物中的应用 | |
CN100381133C (zh) | 一种药物组合物在制备治疗阿斯匹林抵抗的药物中的应用 | |
CN100381135C (zh) | 一种药物组合物在制备治疗阿司匹林抵抗药物中的应用 | |
CN100381134C (zh) | 一种药物组合物在制备抗阿司匹林抵抗药物中的应用 | |
CN110731966B (zh) | 灵仙新苷在治疗雷公藤甲素所致肝损伤的药物中的应用 | |
CN117379503A (zh) | 一种治疗心肌病的中药复方制剂及其制备方法 | |
CN1872248A (zh) | 一种含泽泻的药物在制备治疗阿司匹林抵抗药物中的应用 | |
CN100381139C (zh) | 一种药物组合物在制备抗阿司匹林抵抗药物中的应用 | |
CN1723993A (zh) | 一种药物在抗阿司匹林抵抗药物中的应用 | |
CN1785299A (zh) | 一种含川芎的药物在制备治疗阿司匹林抵抗药物中的应用 | |
CN1872296A (zh) | 一种药物组合物在制备治疗阿司匹林抵抗药物中的应用 | |
CN1872152A (zh) | 一种含藤合欢的组合物在抗阿司匹林抵抗药物中的应用 | |
CN1714827A (zh) | 一种药物在制备治疗阿司匹林抵抗药物中的应用 | |
CN1723975A (zh) | 一种含红花的药物在制备治疗阿司匹林抵抗药物中的应用 | |
CN1872098A (zh) | 一种含银杏提取物的制剂在抗阿司匹林抵抗药物中的应用 | |
CN1714833A (zh) | 一种药物在制备治疗阿司匹林抵抗药物中的应用 | |
Reverentia et al. | Effect of Short-Acting Loop Diuretics on 24-hour Heart Rate Variability and Blood Pressure in Patients with Acute Decompensated Heart Failure | |
CN100411646C (zh) | 一种药物组合物在制备抗阿司匹林抵抗药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: TASLY PHARMACEUTICAL GROUP CO., LTD. Free format text: FORMER NAME: TIANJIN TASLY PHARMACEUTICAL CO., LTD. |
|
CP01 | Change in the name or title of a patent holder |
Address after: 300402 Tianjin science and Technology Park of Beichen Xinyi Road Liaohe Road No. 1 white Patentee after: TASLY PHARMACEUTICAL GROUP Co.,Ltd. Address before: 300402 Tianjin science and Technology Park of Beichen Xinyi Road Liaohe Road No. 1 white Patentee before: Tianjin Tasly Pharmaceutical Co.,Ltd. |
|
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: 300402 Tianjin science and Technology Park of Beichen Xinyi Road Liaohe Road No. 1 white Patentee after: TASLY PHARMACEUTICAL GROUP Co.,Ltd. Address before: 300402 Tianjin science and Technology Park of Beichen Xinyi Road Liaohe Road No. 1 white Patentee before: TASLY PHARMACEUTICAL GROUP Co.,Ltd. |
|
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20071017 |